Medigene
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. The last earnings update was 61 days ago. More info.
Add to Portfolio Compare Print
- Medigene has significant price volatility in the past 3 months.
MDG1 Share Price and Events
7 Day Returns
1 Year Returns
MDG1 Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Medigene (MDG1) | -7.7% | -10.6% | -27.3% | -47.2% | -8.3% | 30.1% |
| DE Biotechs | 0% | 1% | -1% | -14.7% | 75.6% | 10.7% |
| DE Market | -1.8% | 1.6% | -1.6% | -6.7% | 10.1% | 11% |
1 Year Return vs Industry and Market
- MDG1 underperformed the Biotechs industry which returned -14.7% over the past year.
- MDG1 underperformed the Market in Germany which returned -6.7% over the past year.
Value
Is Medigene undervalued based on future cash flows and its price relative to the stock market?
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
- It is not possible to calculate the future cash flow value for Medigene. This is due to cash flow or dividend data being unavailable. The share price is €6.7.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Medigene's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Medigene's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2019-03-31) in EUR | €-0.77 |
| XTRA:MDG1 Share Price ** | XTRA (2019-07-15) in EUR | €6.7 |
| Europe Biotechs Industry PE Ratio | Median Figure of 29 Publicly-Listed Biotechs Companies | 21.17x |
| Germany Market PE Ratio | Median Figure of 419 Publicly-Listed Companies | 20.05x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Medigene.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = XTRA:MDG1 Share Price ÷ EPS (both in EUR) = 6.7 ÷ -0.77 |
-8.75x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Medigene is loss making, we can't compare its value to the Europe Biotechs industry average.
- Medigene is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does
Medigene's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -8.75x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts |
-16.7%per year |
| Europe Biotechs Industry PEG Ratio | Median Figure of 23 Publicly-Listed Biotechs Companies | 1.02x |
| Germany Market PEG Ratio | Median Figure of 270 Publicly-Listed Companies | 1.47x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Medigene, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Medigene's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2019-03-31) in EUR | €4.16 |
| XTRA:MDG1 Share Price * | XTRA (2019-07-15) in EUR | €6.7 |
| Germany Biotechs Industry PB Ratio | Median Figure of 12 Publicly-Listed Biotechs Companies | 3.9x |
| Germany Market PB Ratio | Median Figure of 565 Publicly-Listed Companies | 1.74x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = XTRA:MDG1 Share Price ÷ Book Value per Share (both in EUR) = 6.7 ÷ 4.16 |
1.61x |
* Primary Listing of Medigene.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Medigene is good value based on assets compared to the DE Biotechs industry average.
Value checks
We assess Medigene's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check) Medigene has a total score of 1/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
How is Medigene expected to perform in the next 1 to 3 years based on estimates from 5 analysts?
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare Medigene's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
- Unable to compare Medigene's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
- Medigene's revenue growth is positive but not above the Germany market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| XTRA:MDG1 Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 5 Analysts | -16.7% |
| XTRA:MDG1 Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 5 Analysts | 4.8% |
| Germany Biotechs Industry Earnings Growth Rate | Market Cap Weighted Average | 44.6% |
| Germany Biotechs Industry Revenue Growth Rate | Market Cap Weighted Average | 32.6% |
| Germany Market Earnings Growth Rate | Market Cap Weighted Average | 12.1% |
| Germany Market Revenue Growth Rate | Market Cap Weighted Average | 5.1% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 5 Analyst Estimates (S&P Global) | See Below |
| Date (Data in EUR Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-12-31 | 8 | -48 | -36 | 3 |
| 2020-12-31 | 15 | -29 | -27 | 5 |
| 2019-12-31 | 9 | -28 | -28 | 5 |
| Date (Data in EUR Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2019-03-31 | 8 | -19 | |
| 2018-12-31 | 8 | -10 | -17 |
| 2018-09-30 | 8 | -18 | |
| 2018-06-30 | 8 | -11 | -16 |
| 2018-03-31 | 8 | -16 | |
| 2017-12-31 | 8 | -21 | -16 |
| 2017-09-30 | 8 | -14 | |
| 2017-06-30 | 8 | -7 | -17 |
| 2017-03-31 | 8 | -12 | |
| 2016-12-31 | 7 | -4 | -9 |
| 2016-09-30 | 6 | -8 | |
| 2016-06-30 | 7 | -14 | -7 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (3 months ago) | See Below |
| Future Estimates | Average of up to 5 Analyst Estimates (S&P Global) | See Below |
All data from Medigene Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in EUR Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2021-12-31 | -1.47 | -1.12 | -1.82 | 2.00 |
| 2020-12-31 | -1.14 | -0.86 | -1.60 | 4.00 |
| 2019-12-31 | -1.13 | -1.08 | -1.20 | 3.00 |
| Date (Data in EUR Millions) | EPS * |
|---|---|
| 2019-03-31 | -0.77 |
| 2018-12-31 | -0.72 |
| 2018-09-30 | -0.78 |
| 2018-06-30 | -0.73 |
| 2018-03-31 | -0.75 |
| 2017-12-31 | -0.74 |
| 2017-09-30 | -0.69 |
| 2017-06-30 | -0.81 |
| 2017-03-31 | -0.59 |
| 2016-12-31 | -0.48 |
| 2016-09-30 | -0.41 |
| 2016-06-30 | -0.37 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Medigene will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
Future performance checks
We assess Medigene's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Medigene has a total score of 0/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Medigene performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Medigene does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
- Unable to compare Medigene's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Medigene's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
All data from Medigene Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in EUR Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2019-03-31 | 7.55 | -18.56 | 7.77 | 18.33 |
| 2018-12-31 | 7.58 | -17.05 | 7.62 | 17.12 |
| 2018-09-30 | 8.46 | -18.08 | 7.91 | 17.08 |
| 2018-06-30 | 8.27 | -16.38 | 7.34 | 16.11 |
| 2018-03-31 | 7.84 | -16.48 | 8.05 | 15.58 |
| 2017-12-31 | 7.68 | -15.99 | 8.27 | 14.88 |
| 2017-09-30 | 7.90 | -14.46 | 8.67 | 14.63 |
| 2017-06-30 | 7.88 | -16.56 | 10.36 | 13.90 |
| 2017-03-31 | 7.79 | -11.78 | 9.58 | 12.76 |
| 2016-12-31 | 7.38 | -9.49 | 10.03 | 11.54 |
| 2016-09-30 | 6.17 | -8.17 | 9.75 | 10.30 |
| 2016-06-30 | 6.54 | -7.29 | 8.16 | 9.49 |
| 2016-03-31 | 6.67 | -10.71 | 8.20 | 8.99 |
| 2015-12-31 | 6.81 | -13.00 | 7.62 | 8.53 |
| 2015-09-30 | 10.73 | -10.67 | 6.96 | 8.33 |
| 2015-06-30 | 11.06 | -9.03 | 6.66 | 8.21 |
| 2015-03-31 | 13.04 | -7.39 | 6.62 | 7.83 |
| 2014-12-31 | 12.58 | -5.76 | 7.09 | 7.50 |
| 2014-09-30 | 9.62 | -8.20 | 7.58 | 6.87 |
| 2014-06-30 | 9.23 | -7.47 | 7.85 | 6.57 |
| 2014-03-31 | 8.10 | -9.05 | 7.93 | 6.45 |
| 2013-12-31 | 7.55 | -10.28 | 7.54 | 6.61 |
| 2013-09-30 | 8.49 | -17.43 | 7.81 | 7.35 |
| 2013-06-30 | 7.42 | -17.75 | 7.67 | 7.21 |
| 2013-03-31 | 5.95 | -18.03 | 7.98 | 7.31 |
| 2012-12-31 | 5.87 | -14.88 | 7.92 | 7.40 |
| 2012-09-30 | 3.45 | -13.70 | 8.23 | 7.38 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Medigene has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
- It is difficult to establish if Medigene has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Medigene improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
Past performance checks
We assess Medigene's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Medigene has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Medigene's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Medigene's finances.
The net worth of a company is the difference between its assets and liabilities.
- Medigene is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Medigene's cash and other short term assets cover its long term commitments.
Balance sheet
Assets
Liabilities and shares
- Low level of unsold assets.
- Debt is covered by short term assets, assets are 11.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Medigene Company Filings, last reported 3 months ago.
| Date (Data in EUR Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2019-03-31 | 102.15 | 0.00 | 55.55 |
| 2018-12-31 | 107.43 | 0.00 | 51.41 |
| 2018-09-30 | 104.95 | 0.00 | 44.33 |
| 2018-06-30 | 109.39 | 0.00 | 48.84 |
| 2018-03-31 | 82.81 | 0.00 | 49.10 |
| 2017-12-31 | 93.50 | 0.00 | 51.72 |
| 2017-09-30 | 89.06 | 0.00 | 55.37 |
| 2017-06-30 | 90.36 | 0.00 | 59.87 |
| 2017-03-31 | 74.97 | 0.00 | 48.05 |
| 2016-12-31 | 78.59 | 0.00 | 52.63 |
| 2016-09-30 | 82.05 | 0.00 | 43.60 |
| 2016-06-30 | 87.57 | 0.00 | 48.67 |
| 2016-03-31 | 88.11 | 0.00 | 46.31 |
| 2015-12-31 | 89.99 | 0.00 | 46.76 |
| 2015-09-30 | 91.77 | 0.00 | 50.77 |
| 2015-06-30 | 53.29 | 0.00 | 10.06 |
| 2015-03-31 | 45.86 | 0.00 | 13.15 |
| 2014-12-31 | 49.07 | 0.00 | 14.98 |
| 2014-09-30 | 49.43 | 0.00 | 16.69 |
| 2014-06-30 | 37.38 | 0.00 | 4.10 |
| 2014-03-31 | 37.99 | 0.00 | 7.22 |
| 2013-12-31 | 36.28 | 0.00 | 10.17 |
| 2013-09-30 | 38.87 | 0.00 | 11.66 |
| 2013-06-30 | 40.99 | 0.00 | 14.96 |
| 2013-03-31 | 41.00 | 0.00 | 16.68 |
| 2012-12-31 | 44.17 | 0.00 | 20.11 |
| 2012-09-30 | 45.53 | 0.00 | 22.24 |
- Medigene's level of debt (5.6%) compared to net worth is satisfactory (less than 40%).
- The level of debt compared to net worth has increased over the past 5 years (0% vs 5.6% today).
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Medigene has sufficient cash runway for more than 3 years based on current free cash flow.
- Medigene has sufficient cash runway for more than 3 years if free cash flow continues to reduce at historical rates of -0.2% each year.
Financial health checks
We assess Medigene's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Medigene has a total score of 5/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Medigene's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
€2,000 of
Medigene
shares you are expected to receive
€0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Medigene's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Medigene's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 5 Analyst Estimates (S&P Global) | See Below |
| Europe Biotechs Industry Average Dividend Yield | Market Cap Weighted Average of 9 Stocks | 0.8% |
| Germany Market Average Dividend Yield | Market Cap Weighted Average of 325 Stocks | 3.1% |
| Germany Minimum Threshold Dividend Yield | 10th Percentile | 0.8% |
| Germany Bottom 25% Dividend Yield | 25th Percentile | 1.5% |
| Germany Top 25% Dividend Yield | 75th Percentile | 3.9% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in €) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2021-12-31 | ||
| 2020-12-31 | 0.00 | 1.00 |
| 2019-12-31 | 0.00 | 1.00 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Medigene has not reported any payouts.
- Unable to verify if Medigene's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Medigene's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Medigene afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Medigene has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
| COMPENSATION | €568,000 |
| TENURE AS CEO | 3.4 years |
CEO Bio
Prof. Dr. Dolores J. Schendel has been the Chief Executive Officer and Member of Executive Management Board at MediGene AG since February 1, 2016 and May 1, 2014 respectively. Prof. Dr. has been the Chief Scientific Officer at MediGene AG since February 1, 2016. Prof. Dr. Schendel serves as Director of the Institute of Molecular Immunology and Partner at Helmholtz Zentrum München, GmbH. Prof. Dr. Schendel served as Managing Director of trianta Immunotherapies GmbH and holds a professorship in immunology at the ludwig Maximilians university of Munich. Her research focuses on human immunology and immunotherapy. Prof. Dr. Schendel has served as a Member of the German Cancer aid Grants review panel and as Chair of a life Science Study panel of the european research Council.
CEO Compensation
- Dolores's compensation has been consistent with company performance over the past year, both up more than 20%.
- Dolores's remuneration is about average for companies of similar size in Germany.
Management Team Tenure
Average tenure of the Medigene management team in years:
- The tenure for the Medigene management team is about average.
Management Team
Dolores Schendel
CEO, Chief Scientific Officer & Member of Executive Management Board
€568K
3.4 yrs
Horst Domdey
Co-Founder & Member of the Supervisory Board
€43K
68
25.5 yrs
Kai Pinkernell
Chief Medical Officer
€514K
1.3 yrs
Ernst-Ludwig Winnacker
Co-Founder & Chairman Scientific Advisory Board
€20K
78
Axel-Sven Malkomes
CFO, Chief Business Development Officer and Member of Executive Management Board
0.3 yrs
Board of Directors Tenure
Average tenure and age of the Medigene board of directors in years:
- The average tenure for the Medigene board of directors is less than 3 years, this suggests a new board.
Board of Directors
Gerd Zettlmeissl
Chairman of the Supervisory Board
€26K
64
0.2 yrs
Antoinette Hiebeler-Hasner
Deputy Chairwomen of the Supervisory Board
€35K
2.9 yrs
Horst Domdey
Co-Founder & Member of the Supervisory Board
€43K
68
6.5 yrs
Ernst-Ludwig Winnacker
Co-Founder & Chairman Scientific Advisory Board
€20K
78
1.9 yrs
Frank Mathias
Member of the Supervisory Board
€18K
57
1.2 yrs
Yi-Ta Lee
Member of the Supervisory Board
€25K
6 yrs
Keith Manchester
Member of Supervisory Board
€23K
50
2.2 yrs
Ron Scott
Member of Supervisory Board
€27K
64
2.2 yrs
Micha Drukker
Member of Scientific Advisory Board
1.9 yrs
Peter Krammer
Member of Scientific Advisory Board
53
1.9 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (€) | Value (€) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess Medigene's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Medigene has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
News
Simply Wall St News
Was Medigene AG's (XTRA:MDG1) Earnings Decline Part Of A Broader Industry Downturn?
Below, I will assess MDG1's latest performance announced on 31 March 2018 and weight these figures against its longer term trend and industry movements. … Despite a decline, did MDG1 underperform the long-term trend and the industry. … MDG1 is loss-making, with the most recent trailing twelve-month earnings of -€13.44m (from 31 March 2018), which compared to last year has become.
Simply Wall St - – Full articleInterested In Medigene AG (ETR:MDG1)? Here's How It Performed Recently
Today I will run you through a basic sense check to gain perspective on how Medigene is doing by comparing its latest earnings with its long-term trend as well as the performance of its biotechs industry peers. … Check out our latest analysis for Medigene Was MDG1's recent earnings decline indicative of a tough track record? … Viewing growth from a sector-level, the DE biotechs industry has been growing its average earnings by double-digit 21.92% over the prior twelve months, and 15.19% over the previous five years.
Simply Wall St - – Full articleWhy I Sold Medigene AG (ETR:MDG1)
Whether a company has a good future, in terms of its business operation and financial health, is an important question to address. … MDG1 has high near term liquidity, with short term assets (cash and other liquid assets) amply covering upcoming one-year liabilities, as well as long-term commitments. … One reason I do like MDG1 as a business is its low level of fixed assets on its balance sheet (10.77% of total assets).
Simply Wall St - – Full articleCompany Info
Description
Medigene AG, a biotechnology company, develops immunotherapy platforms to treat a range of cancers in various stages. It operates through two segments, Immunotherapies and Other Products. The company develops Dendritic cell vaccines in phase I/II clinical trials; and T-cell receptor-modified T cells and T-cell-specific monoclonal antibodies in preclinical development phase. It also develops Veregen for the treatment of genital warts; and RhuDex for the treatment of autoimmune diseases. Medigene AG has strategic partnership with bluebird bio, Inc. for the development of T cell receptors; and research collaboration agreements with RXi Pharmaceuticals Corporation. The company was founded in 1994 and is headquartered in Munich, Germany.
Details
| Name: | Medigene AG |
| MDG1 | |
| Exchange: | XTRA |
| Founded: | 1994 |
| €164,532,817 | |
| 24,557,137 | |
| Website: | http://www.medigene.com |
| Address: |
Medigene AG Lochhamer Strasse 11, Planegg/Martinsried, Munich, Bavaria, 82152, Germany |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| XTRA | MDG1 | Common Stock | XETRA Trading Platform | DE | EUR | 30. Jun 2000 | |
| OTCPK | MDGE.F | Common Stock | Pink Sheets LLC | US | USD | 30. Jun 2000 | |
| DB | MDG1 | Common Stock | Deutsche Boerse AG | DE | EUR | 30. Jun 2000 | |
| LSE | 0QGJ | Common Stock | London Stock Exchange | GB | EUR | 30. Jun 2000 | |
| SWX | MDG1 | Common Stock | SIX Swiss Exchange | CH | CHF | 30. Jun 2000 | |
| WBAG | MDG1 | Common Stock | Wiener Boerse AG | AT | EUR | 30. Jun 2000 | |
| BATS-CHIXE | MDG1D | Common Stock | BATS 'Chi-X Europe' | GB | EUR | 30. Jun 2000 |
Number of employees
Current staff
Industry
| Biotechnology | |
| Pharmaceuticals & Biotech |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/07/15 21:05 |
| End of day share price update: | 2019/07/15 00:00 |
| Last estimates confirmation: | 2019/07/08 |
| Last earnings filing: | 2019/05/15 |
| Last earnings reported: | 2019/03/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
